1. Introduction {#s0005}
===============

Chronic periodontitis is an inflammatory disease of the periodontium which is multifactorial. Bacterial plaque is the major etiological factor. Bacteria and their endotoxins play a significant role in periodontal breakdown ([@b0075]).

Thorough subgingival debridement is the cornerstone of non-surgical periodontal therapy in controlling subgingival microflora. Its effectiveness decreases as the probing pocket depth (PPD) increases, especially as PPD exceeds 5 mm ([@b0075]). Supragingival plaque play a contributory role in increasing subgingival bacterial populations ([@b0175], [@b0050], [@b0210], [@b0185]). Effective supragingival plaque control is important in controlling the quantity, composition and rate of subgingival plaque formation and maturation ([@b0090], [@b0115]). It is difficult to achieve long term control over inflammatory periodontal diseases ([@b0155], [@b0140], [@b0030]).

Various adjunctive therapies such as chemotherapeutic agents, local bisphosphonates ([@b0015]), statins ([@b0195]), lasers and photodynamic therapy ([@b0020], [@b0005]) have been employed along with mechanical plaque control regimen ([@b0165]). These therapies have shown variable but promising results.

Natural herbal products have been tested for their antiplaque and antibacterial activity in periodontal diseases. *Acacia arabica* (AA), commonly used in India as chewing stick ('Babul' or 'Kikar' datun) is one of such plant. The gum of AA has been used by many communities in daily oral hygiene regimen ([@b0235]). The composition consists of arabica which is a complex mixture of calcium, magnesium and potassium salts of arabic acid. Other constituents are tannins, cyanogenic glycosides, oxidases, peroxidases and pectinases with documented individual antimicrobial properties ([@b0135]). *In vitro* study provides evidence for the antibacterial and antiprotease activities of AA ([@b0070]).

The gold standard adjunct to scaling and root planing (SRP) is chlorhexidine (CHX) ([@b0010]). Clinical trials comparing AA gum with chlorhexidine have proved its equivalence in plaque inhibition, microbial count reduction and gingivitis resolution without associated adverse effects of CHX ([@b0200], [@b0205]). Therefore long term use of AA can be recommended.

The lacuna in evidence which remains is whether AA gum through inhibition of supragingival plaque would be effective against control of chronic periodontitis. The other hypothetical question is whether certain sites inaccessible to SRP and mechanical plaque control may show better resolution through an adjunctive local application of AA. Clinical trial on the effect of AA on chronic periodontitis is a novel study to the best of our knowledge.

This study was conducted with the objective to analyse the adjunctive effect of AA on clinical parameters in mild to moderate chronic periodontitis patients.

2. Methods {#s0010}
==========

2.1. Study design {#s0015}
-----------------

Pilot, triple-blind, placebo-controlled randomised clinical trial.

Study is approved by Institutional ethics committee of King George's Medical University's (KGMU). The present study is in accordance to the Declaration of Helsinki as revised in 2013.

The trial was registered with the Primary Registries in the *WHO Registry Network (CTRI/2013/09/004013).* Changes in the trial design after ethical approval and trial registration was limited to additional blinding of the statistician.

Participants meeting the eligibility criteria were selected and randomised from the patients coming to the outpatient department of Periodontology, KGMU.

Eighty subjects of both genders aged 18--70 years were recruited in the period from 22nd February 2012 to July 2014. Clinical data collection was completed by November 2014.

2.2. Eligibility criteria {#s0020}
-------------------------

Inclusion: (i) subjects of both gender aged between 18 and 70 years, (ii) in good systemic health condition (iii) with mild to moderate chronic Periodontitis (dentition with at least 30% sites exhibiting attachment loss with pocket depth range of 4--6 mm), having minimum of five natural teeth in each quadrant. Exclusion: (i) Subject with history of tobacco chewing/ smoking, any known clinically significant hematological, endocrine, hepatic, renal, cardiovascular, cerebrovascular or psychiatric disease, (ii) on prohibited medication interfering with the efficacy and safety objectives of the trial, (iii) participant in any clinical study in past 6 months.

Subjects were informed regarding the study's purpose, duration, implications, potential risks and benefits. Willing participants were asked to sign a written informed consent form.

2.3. Sample size calculation {#s0025}
----------------------------

Power analysis for sample calculation was done prior to subject's enrolment for the trial. Assuming a 1 mm difference in Clinical attachment level (CAL) and using 0.8 mm as standard deviation power analysis revealed that 28 patients (total 56 patients in both groups) were required in each group for a *t*-test power level of 85% with significance level of 0.95 ([@b0065]). Recruitment of additional patients accounting noncompliance and follow up dropouts were done.

2.4. Clinical periodontal assessment {#s0030}
------------------------------------

Baseline examination consisted of recording Periodontal probing depth (PPD) and CAL (at four sites per tooth: mesial, buccal, distal and lingual); Plaque Index ([@b0160]); dichotomous recording of bleeding on probing (BOP) ([@b0025]) and Gingival index (GI) ([@b0160]). Positive reading meant bleeding occurrence within 15 s of pocket probing.

PPD was defined as the distance between the gingival margin (GM) and the bottom of the probeable pocket, to the nearest whole millimetre. CAL was calculated as the distance between the cemento enamel junction (CEJ) and the bottom of the probeable pocket, to the nearest whole millimetre.

All measurements were done using the manual periodontal probe with William's marking (*University of Michigan 'O' probe, Hu Friedy, Chicago, IL, USA*) and the pressure sensitive probe (*FP32, Florida probe Corporation, Gainesville, FL, USA).*

Clinical periodontal parameters were assessed at baseline, 15 days and 90 days after SRP.

2.5. Outcome variables {#s0035}
----------------------

Primary outcome variables are probing pocket depth reduction and clinical attachment level. Secondary outcome variables are bleeding on probing, change in clinical gingival health and change in plaque scores.

2.6. Intraexaminer validity {#s0040}
---------------------------

Periodontal assessment was performed by one calibrated examiner (PR).

The examiner evaluated the subjects on two occasions at 0 and 2 days. Calibration was validated as 90% of the readings were reproduced within a 1.0 mm difference. The same calibration was validated on manual and Florida probe system for intra-examiner reproducibility. These recordings were done by a single investigator (PR).

2.7. SRP and the use of the gel {#s0045}
-------------------------------

After baseline recordings, thorough scaling and root planing (SRP) was performed similarly for all patients by a single periodontist (RS). The periodontal scaling was performed on two consecutive sittings using an ultrasonic scaler under saline irrigation followed by root planing using hand instruments.

The area for application of the treatment/ placebo gel was then demarcated. The subjects were randomised into two groups and asked to use the given gel on a set of 2--4 teeth (premolars and molars) in one specified quadrant. These were then termed as the test teeth.

2.8. Blinding {#s0050}
-------------

Enrolled participants in both arms, treating periodontologists, study coordinators and analysing statistician were blinded to treatment.

2.9. Randomisation and allocation concealment {#s0055}
---------------------------------------------

AA and placebo gel were supplied as similarly labelled identical plain white tubes pre-coded by the manufacturer intermixed in the supplied box. Box was so sealed as to allow only hand space for tube retrieval and dispensation randomly. An investigator blinded to patient's clinical data dispensed the tubes (ST).

For further allocation concealment, another investigator (RK) totally unaware of the study design, patient's condition and other details maintained the records of the codes. New gel tube was provided every 15 days. Same investigator dispensed new gel after matching the tube code.

2.10. Product description and usage protocol {#s0060}
--------------------------------------------

Coded tubes contained either AA gel or placebo. Gels were similar in taste, consistency, colour and texture.

Gel usage instructions were given by investigator involved in active treatment (RS). Patients were instructed to apply the gel on the gingiva overlying the test teeth after tooth brushing, twice daily; morning and evening. Gel was to be massaged over the area for 1 min such that it seeps into the gingival sulcus. Patients were told not to rinse after gel application and avoid eating for an hour post application of gel.

Patients were instructed to bring the tubes on recall visits which were every 15 days to check for compliance. New gel tubes were then dispensed. Patients were asked regarding the general health changes, ulceration, and soreness in treatment application area, taste perturbation or any other adverse events by the treatment examiner (RS). Assessment was also done for any colour changes or staining of the teeth and the gingiva.

2.11. Statistical analysis {#s0065}
--------------------------

Blinded statistician was provided the coded data. Analysis was done between two coded groups. After statistical analysis the codes of the tubes were broken as provided by the manufacturer in the sealed opaque envelope at the time of product delivery. The SRP + AA gel was assigned Group I and SRP + placebo gel was assigned as Group II. Results were further interpreted on this basis.

Statistical analysis consisted of testing the time bound intragroup and intergroup differences between active and placebo group. The data set was tested for normality of distribution.

Qualitative data was assessed using chi square test. Intragroup comparison for continuous variables was done using the *student 't' test*. Intergroup comparison for the research question; whether the post-test means, adjusted for pre-test scores, differ between the two groups; was done using *analysis of covariance (ANCOVA)*.

3. Results {#s0070}
==========

Flow chart for the study is shown in [Fig. 1](#f0005){ref-type="fig"}. Thirteen patients were lost to follow up (Group I: 4; Group II: 9) and eight dropped from analysis due to non-compliance of treatment protocol (Group I: 5; Group II: 3).Fig. 1Flow diagram.

Final analysis was done for 59 patients. Group I consisted of 31 patients with 102 teeth assessed at 408 sites. Group II consisted of 28 patients with assessment done for 89 teeth at 356 sites.

Adverse events were not reported by patients or observed by investigators on continuous gel usage. Demographic data is shown in [Table 1](#t0005){ref-type="table"}.Table 1Demographical data.ParametersGroup I\
(N = 31)Group II\
(N = 28)P ValueAge (yrs)[\*](#tblfn1){ref-type="table-fn"}0.037 Mean33.2339.11 SD09.2411.62 Range18.00--55.00 yrs20.00--60.00 yrs  Sex (%) Male16 (51.6)16 (57.1)0.670 Female15 (48.4)12 (42.9)NS[^1][^2]

3.1. Primary outcomes {#s0075}
---------------------

### 3.1.1. Probing pocket depth {#s0080}

Mean baseline PPD was similar in both the groups ([Table 2](#t0010){ref-type="table"}). Data was analysed in two parts; mild pocket areas: 0--4 mm and moderate pocket sites: 4--6 mm.Table 2Comparison of change in mean percentage of sites with pocket probing depth between two groups.Duration in daysMean percentage of sites with pocket probing depthP Value\
(GROUP I vs II)Group I\
(N = 102)Group II\
(N = 085)% site PPD\
0--4\
(in mm)% site PPD\
4--6\
(in mm)% site PPD\
0--4\
(in mm)% site PPD\
4--6\
(in mm)% site PPD\
0--4\
(in mm)% site PPD\
4--6\
(in mm)Baseline\
(Mean ± SD)52.21 ± 22.5547.79 ± 22.5548.82 ± 26.7051.18 ± 26.700.355\
NS0.355\
NS15\
(Mean ± SD)73.28 ± 24.1826.72 ± 24.1867.06 ± 25.9432.94 ± 25.9490\
(Mean ± SD)94.12 ± 11.7605.88 ± 11.7675.29 ± 21.3024.71 ± 21.30Mean Diff. between Baseline -- 15 days\
(P value)[\*](#tblfn2){ref-type="table-fn"}21.07 ± 21.90\
(0.001)[\*](#tblfn2){ref-type="table-fn"}−21.07 ± 21.90\
(0.001)[\*](#tblfn2){ref-type="table-fn"}18.24 ± 22.62\
(0.001)[\*](#tblfn2){ref-type="table-fn"}−18.24 ± 22.62\
(0.001)0.387\
NS0.388\
NSMean change between groups\
(B -- D15)**2.832.83**Mean Diff. between Baseline -- 90 days\
(P value)[\*](#tblfn2){ref-type="table-fn"}41.91 ± 23.90\
(0.001)[\*](#tblfn2){ref-type="table-fn"}−41.91 ± 23.90\
(0.001)[\*](#tblfn2){ref-type="table-fn"}26.47 ± 27.37\
(0.001)[\*](#tblfn2){ref-type="table-fn"}−26.47 ± 27.37\
(0.001)[\*](#tblfn2){ref-type="table-fn"}0.001[\*](#tblfn2){ref-type="table-fn"}0.001Mean change between groups\
(B -- D90)**15.4415.44**[^3][^4]

The change between the groups in mean percentage of sites with PPD 0--4 mm and 4--6 mm was 2.83% respectively which is comparable and non-significant (p = .387).

The reduction in sites with moderate PPD was observed more among Group I than Group II and the difference was statistically significant (p = .001).

### 3.1.2. Clinical attachment level {#s0085}

Clinical attachment level was divided into 3 groups for analysis: CAL between 0--4 mm, between 4--6 mm and \>6 mm. Teeth with PPD between 4--6 mm with recession present had CAL \>6 mm. Baseline mean percentage of sites with CAL is shown in [Table 3](#t0015){ref-type="table"}.Table 3Comparison of change in mean percentage of sites with cal between two groups.Duration in daysMean percentage of sites with CALP Value\
(GROUP I vs II)Group I\
(N = 102)Group II\
(N = 085)% site CAL\
0--4% site CAL\
4--6% site CAL\
 \>6% site CAL\
0--4% site CAL\
4--6% site CAL\
 \>6% site CAL\
0--4% site CAL\
4--6% site CAL\
 \>6Baseline\
(Mean ± SD)25.49 ± 24.1144.85 ± 23.4329.66 ± 22.7327.06 ± 24.7645.59 ± 29.4227.35 ± 23.350.662\
NS0.851\
NS0.496\
NS15\
(Mean ± SD)42.89 ± 30.5448.04 ± 28.5109.07 ± 13.9837.65 ± 26.3456.47 ± 28.1205.88 ± 13.7290\
(Mean ± SD)64.22 ± 28.0435.05 ± 27.5300.74 ± 04.2439.20 ± 27.9354.63 ± 30.6506.17 ± 13.42Mean Diff. between Baseline -- 15 days\
(P value)[\*](#tblfn3){ref-type="table-fn"}17.40 ± 23.81\
(0.001)03.19 ± 35.30\
(0.393)\
NS[\*](#tblfn3){ref-type="table-fn"}20.59 ± 22.36\
(0.001)[\*](#tblfn3){ref-type="table-fn"}10.59 ± 15.61\
(0.001)[\*](#tblfn3){ref-type="table-fn"}10.88 ± 27.13\
(0.001)[\*](#tblfn3){ref-type="table-fn"}21.47 ± 22.54\
(0.001)[\*](#tblfn3){ref-type="table-fn"}0.0200.094\
NS0.789\
NSMean change between groups (B -- D15)06.81−07.69−00.88Mean Diff. between Baseline -- 90 days\
(P value)[\*](#tblfn3){ref-type="table-fn"}38.73 ± 25.52\
(0.001)[\*](#tblfn3){ref-type="table-fn"}−09.80 ± 35.21\
(0.006)[\*](#tblfn3){ref-type="table-fn"}28.92 ± 23.00\
(0.001)[\*](#tblfn3){ref-type="table-fn"}12.65 ± 20.20\
(0.001)[\*](#tblfn3){ref-type="table-fn"}09.57 ± 27.55\
(0.002)[\*](#tblfn3){ref-type="table-fn"}22.22 ± 25.22\
(0.001)[\*](#tblfn3){ref-type="table-fn"}0.0010.961\
NS0.065\
NSMean change between groups\
(B -- D90)26.0800.2306.70[^5][^6]

Percentage of sites with CAL \>6 mm at day 15 and day 90 was comparable for Group I and II with statistically non-significant difference.

The percentage of sites with CAL 4--6 mm, at day 90 in both groups showed a significant reduction. On intergroup comparisons, both the groups had comparable CAL gain in sites with CAL 4--6 mm at day 15 and 90 (p = .094; 0.961).

Mean percentage of sites with CAL 0--4 showed statistically significant gain in Group 1 compared to Group II.

3.2. Secondary variables {#s0090}
------------------------

### 3.2.1. Plaque index (PI) {#s0095}

PI was assessed in groups of 0--2 and 2--3 ([Table 4](#t0020){ref-type="table"}).Table 4Comparison of change in mean percentage of sites with plaque index between two groups.Duration in daysMean percentage of sites with Plaque indexP Value\
(Group I Vs II)Group I\
(N = 102)Group II\
(N = 089)% site PI 0--2% site PI 2--3% site PI 0--2% site PI 2--3% site PI 0--2% site PI 2--3Baseline\
(Mean ± SD)60.78 ± 29.3335.78 ± 29.5462.08 ± 29.9433.99 ± 29.970.763\
NS0.679\
NS15\
(Mean ± SD)01.47 ± 06.8800.00 ± 00.0000.56 ± 03.7300.00 ± 00.0090\
(Mean ± SD)02.21 ± 07.1300.00 ± 00.0042.70 ± 32.6804.21 ± 15.19Mean Diff. between Baseline -- 15 days\
(P value)[\*](#tblfn4){ref-type="table-fn"}−59.31 ± 32.42\
(0.001)[\*](#tblfn4){ref-type="table-fn"}−35.78 ± 29.54\
(0.001)[\*](#tblfn4){ref-type="table-fn"}−61.52 ± 29.69\
(0.001)[\*](#tblfn4){ref-type="table-fn"}−33.99 ± 29.97\
(0.001)0.623\
NS0.679\
NSMean change between groups\
(B -- D15)−2.2101.79Mean Diff. between Baseline -- 90 days\
(P value)[\*](#tblfn4){ref-type="table-fn"}−58.57 ± 30.36\
(0.001)[\*](#tblfn4){ref-type="table-fn"}−35.78 ± 29.54\
(0.001)[\*](#tblfn4){ref-type="table-fn"}−19.38 ± 44.55\
(0.001)[\*](#tblfn4){ref-type="table-fn"}−29.78 ± 30.82\
(0.001)[\*](#tblfn4){ref-type="table-fn"}0.0010.173\
NSMean change between groups\
(B -- D90)39.1906.00[^7][^8][^9][^10]

At the end of 90 days, mean percentage of sites with PI 0--2 and 2--3 showed a change of 58.57% and 35.78% for Group I and 19.38% and 29.78% for Group II respectively from baseline.

### 3.2.2. Gingival index {#s0100}

At 90 days, mean percentage of sites with GI 0, 1 and ≥2 showed significant change of 43.14%, 40.93% and 84.07% respectively for Group I and change of 6.74%, 36.80% and 43.54% respectively for Group II ([Table 5](#t0025){ref-type="table"}).Table 5Comparison of change in mean percentage of sites with gingival index between two groups.Duration in daysMean percentage of sites with gingival index\
($\mathit{overlineX}$ ± SD)P Value\
(Group I Vs II)Group I\
(N = 102)Group II\
(N = 089)% site GI 0% site GI 1% site GI ≥2% site GI 0% site GI 1% site GI ≥2% site GI 0% site GI 1% site GI ≥2Baseline\
(Mean ± SD)00.00 ± 00.0007.60 ± 18.5592.40 ± 18.5501.69 ± 11.1806.74 ± 19.1391.57 ± 21.630.155\
NS0.754\
NS0.777\
NS15\
(Mean ± SD)46.81 ± 24.7948.78 ± 23.7004.41 ± 10.2028.65 ± 30.7562.64 ± 31.5608.71 ± 15.1290\
(Mean ± SD)43.14 ± 28.4048.53 ± 27.6608.33 ± 16.6308.43 ± 20.6243.54 ± 29.5648.03 ± 32.90Mean Diff. between Baseline -- 15 days\
(P value)[\*](#tblfn5){ref-type="table-fn"}46.81 ± 24.79\
(0.001)[\*](#tblfn5){ref-type="table-fn"}41.18 ± 31.20\
(0.001)[\*](#tblfn5){ref-type="table-fn"}−87.99 ± 20.73\
(0.001)[\*](#tblfn5){ref-type="table-fn"}26.96 ± 28.76\
(0.001)[\*](#tblfn5){ref-type="table-fn"}55.90 ± 40.42\
(0.001)[\*](#tblfn5){ref-type="table-fn"}−82.87 ± 23.72\
(0.001)[\*](#tblfn5){ref-type="table-fn"}0.001[\*](#tblfn5){ref-type="table-fn"}0.0060.116\
NSMean change between groups\
(B -- D15)19.85−14.725.12Mean Diff. between Baseline -- 90 days\
(P value)[\*](#tblfn5){ref-type="table-fn"}43.14 ± 28.40\
(0.001)[\*](#tblfn5){ref-type="table-fn"}40.93 ± 34.61\
(0.001)[\*](#tblfn5){ref-type="table-fn"}−84.07 ± 27.88\
(0.001)[\*](#tblfn5){ref-type="table-fn"}06.74 ± 17.98\
(0.001)[\*](#tblfn5){ref-type="table-fn"}36.80 ± 35.17\
(0.001)[\*](#tblfn5){ref-type="table-fn"}−43.54 ± 37.60\
(0.001)[\*](#tblfn5){ref-type="table-fn"}0.0010.416\
NS[\*](#tblfn5){ref-type="table-fn"}0.001Mean change between groups\
(B -- D90)36.44.1340.53[^11][^12][^13][^14]

4. Discussion {#s0105}
=============

Within its limitations, this triple blind placebo controlled randomised clinical trial provides evidence for improvement in clinical parameters through adjunctive use of AA containing gel in mild to moderate chronic periodontitis patients. Significant probing pocket depth reduction and CAL gain was observed with adjunctive use of AA gel. Secondary parameters of plaque control and BOP showed better outcomes in AA gel group compared to SRP alone.

The shift in pocket probing depths for both the groups from sites with moderate pocket depth 4--6 mm towards sites with mild pocket depths 0--4 mm occurred on day 15 and day 90 ([Table 2](#t0010){ref-type="table"}). This shift was comparable in both the groups at day 15 but more in Group I compared to Group II on day 90 (p = .001). Poor supragingival plaque control may lead to reestablishment of the subgingival microbiota within 40--60 days following subgingival debridement ([@b0210]). AA gel has proven efficacy against supragingival plaque ([@b0205], [@b0105], [@b0225]). An *in vitro* study by Clark et al. revealed protease activity inhibition in the presence of 0.5% w/v of AA gum sonicates ([@b0070]). Trypsin-like activities of *Porphyromonas gingivalis* and *Prevotella intermedia* were found to be highly sensitive to AA gum ([@b0070]). Detectable levels of *P gingivalis* and *P intermedia* are associated with chronic periodontal disease progression and their elimination by therapy leads to improved clinical response ([@b0095], [@b0060], [@b0215], [@b0110]). Greater PPD reduction in Group I could be attributed to the antiprotease inhibition of *P gingivalis* and *P intermedia* by AA gel.

The results of the systematic reviews comparing the use of local adjuncts to SRP in periodontal disease have shown local chemotherapeutics to be modestly effective in PPD reduction than SRP alone ([@b0045], [@b0085]). Microbiological and biomarker studies may provide further evidence for the clinical efficacy of AA gel seen in the present clinical trial.

The mean percentages of sites with CAL from \>6 mm and 4--6 mm showed CAL gain. Mean sites with CAL 0--4 mm showed further CAL gain in both the groups at analysed two time periods. The studies related to the use of local adjuncts to SRP in a systematic review had shown CAL gains to be smaller and statistical significance less common ([@b0045]). Marginal improvements in CAL were found to be a fraction compared to SRP alone ([@b0045]).

At 90 day analysis, both groups showed good plaque control (PI 0--2). The mean percentage of sites was significantly more in Group I than group II. Not all patients may respond well to therapy or maintain stable oral hygiene regimen over extended periods of time following successful therapy ([@b0245], [@b0250]), explaining the equal distribution in both groups of subjects with poor plaque scores (PI 2--3).

Increase in number of sites with PI 0--2 suggests anti plaque activity of AA gel. Improvements seen are similar to various studies utilising AA gum as toothpaste, chewing gum, gel and powder ([@b0200], [@b0205], [@b0105], [@b0225]). PI scores with local application of AA gel are proven to be comparable to local CHX use ([@b0200], [@b0205]). The anti-plaque activity of AA may also be related to the decrease in PPD in Group I ([@b0090], [@b0115]).

At the end of 90 days increased sites in Group I showed improved GI status compared to Group II. AA gel is associated with reduction in microbial counts of *Streptococcus sanguis, S mitis, S intermedius, S oralis, Actinomyces viscosus* and *A naeslundii* ([@b0205]). These are gram positive bacteria associated with gingivitis ([@b0170]). Their reduction would result in resolution of gingival inflammation and hence improved GI status ([@b0040]). Further, these bacteria are associated with early plaque colonisation ([@b0150]). Their reduction may also be the reason for improved PI status in Group I.

Bleeding on Probing showed significant reduction in groups at day 15 which was sustained for Group I at Day 90. Improvement in BOP may be related to decreased plaque accumulation and better gingival status ([@b0200], [@b0205], [@b0105]). Study using AA containing toothpaste showed similar reduction in BOP at 28 days re-evaluation ([@b0225]). Tannins, a constituent of AA gum have astringent and hemostatic properties ([@b0035]) and may lead to improvement in BOP and GI status. Reduction in number of sites with *P gingivalis* activity also leads to reduction in BOP ([@b0180], [@b0230]).

Mild to moderate periodontitis cases were assessed for localised response of the gel in the present study. The role of supragingival plaque control has been proven to be effective in mild to moderate cases but not on advanced periodontal disease ([@b0130], [@b0240]). In deep pockets, local penetration of the gel was not possible. Other variables in deep pockets may have served as study confounders. Studies have revealed areas in deep pockets to be prone to residual plaque and calculus even after thorough scaling and root planing ([@b0120], [@b0055], [@b0100], [@b0220], [@b0145]). Non-surgical periodontal therapy alone is considered ineffective in patients with severe periodontitis exceeding PPD \>6 mm ([@b0075]).

The strengths of the study is that it is the first study utilising AA gum gel for analysis as an adjunct to SRP in control and maintenance of mild to moderate periodontitis patients. This clinical trial was designed according to *CONSORT 2010 guidelines* considering the suggestions laid by other researchers on trial design in non-surgical periodontal therapy ([@b0125], [@b0190], [@b0080]).

The limitations of this study are that it does not assess bone defect fill. Radiographic assessment for defect fill could have been more representative of true periodontal healing. Another limitation is the short follow-up period.

5. Conclusion {#s0110}
=============

Within its limitations, the trial has shown clinical improvement in Probing pocket depth, clinical attachment level, plaque index, gingival index and bleeding on probing. Further studies exploring AA gum as local drug delivery agent and its properties of susbstantivity, microbial inhibitions, effect on inflammatory markers may be beneficial for long term maintenance of periodontitis patients.
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